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Neonates are clearly more susceptible to severe disease following infection with a variety of pathogens than are adults.
However, the causes for this are unclear and are often attributed to immunological immaturity. While several aspects of
immunity differ between adults and neonates, the capacity of dendritic cells in neonates to process and present antigen to
CD8
+ T cells remains to be addressed. We used human CD8
+ T cell clones to compare the ability of neonatal and adult
monocyte-derived dendritic cells to present or process and present antigen using the MHC class I pathway. Specifically, we
assessed the ability of dendritic cells to present antigenic peptide, present an HLA-E–restricted antigen, process and present an
MHC class I-restricted antigen through the classical MHC class I pathway, and cross present cell-associated antigen via MHC
class I. We found no defect in neonatal dendritic cells to perform any of these processing and presentation functions and
conclude that the MHC class I antigen processing and presentation pathway is functional in neonatal dendritic cells and hence
may not account for the diminished control of pathogens.
Citation: Gold MC, Robinson TL, Cook MS, Byrd LK, Ehlinger HD, et al (2007) Human Neonatal Dendritic Cells Are Competent in MHC Class I Antigen
Processing and Presentation. PLoS ONE 2(9): e957. doi:10.1371/journal.pone.0000957
INTRODUCTION
About 2 million children die each year of infectious diseases
(World Health Organization Maternal Health and Safe Mother-
hood Programme MSM96.7, 1996). Young infants are more
susceptible to severe disease from infectious pathogens than are
older children and adults [1]. Specifically, infections with
respiratory syncytial virus, HIV, Streptococcus pneumoniae, Mycobac-
terium tuberculosis (Mtb) and Plasmodium sp. disproportionately cause
morbidity and mortality in infants [2]. The causes for this are
likely to be pleomorphic, and include the reduced frequency and
diminished functional capacity of neonatal T cells [3]. While
studies in both humans and mice demonstrate decreased T cell
function in neonates, this defect can be overcome by the
administration of strong adjuvants [4]. These data suggest that
the defect might rest in the priming of naı ¨ve T cells. Dendritic cells
(DC) are unique in their capacity to present processed antigen to
prime naı ¨ve T cells in vivo: CD4
+ T cells via the MHC II pathway,
and CD8
+ T cells via the MHC I pathway, respectively [5]. The
results from studies evaluating the MHC II antigen processing and
presentation pathway in neonates are equivocal but current
reviews suggest neonatal DC may be defective in this regard [3,6].
However, little is known about the functionality of DC in antigen
processing and presentation via the MHC I pathway in neonates.
Ultimately, the most stringent functional test of DC function is
their capacity to prime optimal T cell responses in vivo. While this
is difficult to evaluate in humans, Salio et al. showed that DC from
neonates could efficiently prime CD8
+ T cells in vitro. However,
priming was performed using DC loaded with antigenic peptide
and again these DC were not tested for their ability to present
processed antigen. To prime cytolytic CD8
+ T cells, dendritic cells
must first process cytosolic or exogenously-acquired antigens, load
them onto newly synthesized MHC class I molecules, and
transport the loaded MHC I molecules to the cell surface where
they are available to stimulate CD8
+ T cells. To date, no study has
directly evaluated the capacity of human neonatal DC to process
and present MHC class I antigens to CD8
+-restricted T cells.
Therefore, to address the hypothesis that the increased severity of
disease associated with neonates is due to a defect in DC MHC I
antigen processing and presentation, we performed a comprehen-
sive study using monocyte-derived DC isolated from neonatal cord
blood mononuclear cells (CBMC) and adult peripheral blood
mononuclear cells (PBMC). We assessed the ability of DC to
present antigenic peptide, present a MHC class Ib (HLA-E)-
restricted antigen, process and present a MHC class Ia antigen
delivered through viral infection, and finally, cross present cell-
associated antigen. This thorough functional examination of
neonatal DC demonstrates that these cells are fully competent
APC in their ability to process and present antigen to CD8
+ Tc e l l s .
RESULTS
To directly assess the functional capacity of DC, experimental
conditions have been established in which the activation of CD8
+
T cells is dependent on the availability of functional APC [7]. In
brief, DC are titrated in the presence of excess numbers of T cell
clones such that T cell activation is limited by the availability of
DC. To first evaluate the MHC I antigen presentation pathway in
neonatal DC, we assessed the capacity of DC to present a minimal
peptide epitope to cognate CD8
+ T cells, an assay reflective of the
density of HLA-I on the cell surface. Specifically, we assessed the
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PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e957ability of DC to present an HLA-A2-restricted peptide to the
HLA-A2-restricted, HCMV pp65(495-503) NLVPMVATV-specific
CD8
+ T cell clone D2 1-D2. Here, we observed equivalent
presentation of the HCMV pp65 peptide over a range of
concentrations by neonatal (n=7) and adult (n=4) DC (Figure 1,
p=0.9882).
HLA class Ib-restricted responses are also associated with certain
pathogens [8]. Notably, roughly fifty percent of the CD8
+ T cell
response to Mtb is comprised of non-classical MHC Ib-restricted T
cells [9]. Therefore, we sought to evaluate the presentation of an
MHC class Ib-restricted antigen by neonatal DC. The CD8
+ T cell
clone D160 1-23 recognizes an HLA-E-restricted antigen derived
from the cell wall of Mtb [10]. Therefore, we incubated DC with
pronase-treated Mtb cell wall and assessed the ability of clone D160
1-23 to produce IFN-c. Again, neonatal DC (n=6) were equally
capable as adult DC (n=5) to stimulate HLA-E-restricted CD8
+ T
cells (Figure 2, p=0.7943).
Given the enhanced susceptibility of neonates to viral infection,
we postulated that neonatal DC may be deficient in their ability to
process intracellular antigen in the context of HLA-I. To address
this possibility, we infected DC with vaccinia virus expressing the
HCMV antigen pp65. We then titrated the DC over a range and
assessed the ability of cognate T cell clone D2 1-D2 to produce
IFN-c by ELISPOT. Figure 3 shows no significant difference in
the ability of neonatal DC (n=7) compared to adult DC (n=11) to
present the vaccinia-delivered pp65 antigen to HLA-A2-restricted
CD8
+ T cell clone D2-1-D2 (p=0.6489).
As a professional APC, DC can be distinguished from a non-
professional APC in the ability to process and present exogenous
cell-associated antigens on MHC class I molecules in a process
known as cross presentation. Moreover, DC are crucial in priming
naı ¨ve CD8
+ T cells and this process most likely occurs with cross
presented antigen in vivo [11]. Therefore, we sought to test the
ability of DC to cross present cell-associated antigen. To assess the
cross presentation pathway, we have established an experimental
system that requires cell-associated antigen be processed and
presented by an HLA-mismatched APC. In brief, HLA-A2-
negative LCL are infected with vaccinia expressing the HCMV
(vvpp65). Heat inactivation and UV irradiation are performed to
prevent further viral replication and induce apoptosis in the LCL,
respectively. HLA-A2-positive DC are then co-incubated with the
Figure 1. Equivalent peptide presentation of the HCMV pp65
nonamer NLVPMVATV by DC from adult and neonatal blood to
HLA-A2- restricted clone CD8
+ T cell clone D2-1-D2. The peptide
NLVPMVATV was added in 10-fold dilutions (final concentration
10,000 pg/ml to 10 pg/ml) to HLA-A2
+ monocyte-derived DC (20,000
cells/well) from adult (n=4) and neonatal (n=7) blood and incubated
overnight with D2-1-D2 CD8
+ T cell clones (10,000 cells/well). IFN-c
production was detected by ELISPOT. Linear regression analysis was
used to determine that there was no statistically significant difference
between adult and neonatal DC in presentation of peptide to HLA-2-
restricted CD8
+ T cells (p=0.9882). Monocyte-derived DC (MDDC) were
used as antigen presenting cells in all experiments and were derived as
described in materials and methods.
doi:10.1371/journal.pone.0000957.g001
Figure 2. DC from adults and neonates are comparable in their ability
to present the M. tuberculosis antigen pronase-digested cell wall to
HLA-E-restricted clone D160-1-23. DC from adult (n=5) and neonatal
(n=6) blood were incubated overnight with or without the pronase-
treated cell wall fraction from M.tuberculosis. The DC were diluted over
a range of concentrations (90,000 to 1100 cells/well), and incubated
with the cognate CD8
+ HLA-E-restricted clone D160-1-23 (10,000 cells/
well) overnight. IFN-c was detected by ELISPOT. There was no
statistically significant difference between adult and neonatal DC in




Figure 3. DC from adult and neonatal blood are similar in their ability
to process and directly present the HLA-A2 restricted antigen HCMV
pp65 epitope NVLPMVATV following recombinant vaccinia infection.
HLA-A2
+ DC from adults (n=11) and neonates (n=7) were infected
with vvpp65 (moi=1.5) overnight. Infected and uninfected DC were
titrated over a range (10,000 to 1,100 cells/well) and incubated
overnight with pp65-specific CD8
+ T cell clone D2-1-D2 (10,000 cells/
well). IFN-c production was detected by ELISPOT. HLA-A2
2 DC from
both adults and neonates did not induce any IFN-c production by CD8
+
T cell clone D2-1-D2. There was no statistically significant difference
between adult and neonatal DC in processing and directly presenting
antigen following recombinant vaccinia infection (p=0.6489).
doi:10.1371/journal.pone.0000957.g003
Neonatal DC Are Competent APC
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assessed via the release of IFN-c by the cognate HLA-A2-restricted
CD8
+ T cell clone (D2 1-D2 specific for the HCMV pp65 peptide,
NLVPMVATV). In each experiment we rule out the possibility of
viralspreadordirectpresentation.Forthiscontrol,HLA-A2-positive
LCL, which unlike DC cannot cross present cell-associated antigen,
are co-incubated with the vvpp65-infected HLA-A2-negative LCL
either before or after virus inactivation. In all experiments, only the
addition of vvpp65-infected HLA-A2-negative LCL that were not
heat treated, to the HLA-A2-positive LCL, stimulated the CD8
+ T
cell clone D2-1-D2 (Figure 4a). To assess cross presentation, HLA-
A2-positive DC from neonates and adults were incubated with the
HLA-A2-negative LCL that were either infected with vaccinia
(Figure 4b) or not and treated as described above. HLA-A2-negative
DC did not cross present HCMV antigen pp65 (Figure 4b). HLA-
A2-positive DC from neonates (n=14) and adults (n=18) were
equivalent in their ability to cross present the HLA-A2-restricted
antigen HCMV pp65 (Figure 4c, p=0.8587).
DISCUSSION
Few reports exist to demonstrate whether or not antigen
processing and presentation in neonates is functionally impaired.
Studies using MLR to assess the MHC II pathway have yielded
conflicting conclusions [12–14]. The most comprehensive study of
MHC II antigen processing and presentation function in neonates
was performed using cord blood-derived monocytes as APC. Here,
a defect in the presentation, but not in the processing of MHC II
antigens was demonstrated [15]. To the best of our knowledge, no
report exists on the ability of human neonatal DC to process and
present antigen via the MHC class I pathway.
CD8
+ T cells are involved in the control of many viral, bacterial
and protozoan pathogens [16]. Consequently, a defect in the
CD8
+ T cell-dependent recognition of intracellular pathogens
could have a profound effect on the control of these pathogens. We
functionally assessed presentation of MHC I antigens in neonatal
DC and found no defect in the presentation of both MHC Ia and
MHC Ib-restricted antigens. To evaluate the ability of neonatal
DC to process and present cytosolic proteins using the well-defined
classical MHC class I pathway, we delivered the antigen in the
context of live virus infection. Here, antigens generated in the
cytosol are degraded into peptides via the proteasome, transported
via TAP into the ER, loaded onto newly synthesized MHC class I
molecules, transported to the cell surface, where they can be
recognized by CD8
+ T cells. Our studies show that neonatal DC
showed no defect in their ability process and present antigen via
this classical MHC I pathway.
In vivo, DC that are not directly infected by pathogens can still
prime CD8
+ T cells through a mechanism known as cross priming
[17]. Here, DC are uniquely capable of engulfing dying cells and
presenting the exogenously acquired antigens onto MHC class I
molecules using the ill-defined cross presentation pathway. More
importantly, cross presented antigen is likely to be the primary
mechanism by which CD8
+ T cells are primed in vivo [11].
Consequently, defects in the cross presentation pathway could
limit the acquisition of pathogen-specific adaptive immunity.
Fonteneau et al. characterized the cross presentation pathway for
cell-associated antigen in human DC from PBMC [18]. These
authors showed that cross presentation of the cell-associated (either
apoptotic or necrotic cells) influenza A matrix protein 1 required:
phagocytosis or macropinocytosis, proteolysis by cathepsin D, the
proteasome, TAP, transfer of the antigen from the phagosome to
the MHC class I loading complex with newly synthesized class I
molecules, and export of peptide-loaded MHC I to the cell surface.
Only one step in this pathway, the ability of neonatal DC to take
up necrotic or apoptotic LCL, has been assessed. In this case,
Wong et al. found no defect in the ability of neonatal DC to take
up exogenous cells [19]. Our studies support those conclusions and
significantly advance our understanding of neonatal DC function.
Ultimately, we found no defect in the ability of neonatal DC to
perform the multiple sequential steps that culminate in the
complex process of cross presentation.
Why are neonates defective in generating functional immune
responses to pathogens in vivo? Our studies suggest that DC from
Figure 4. DC from adults and neonates are equivalent in their ability
to cross present cell-associated antigen.
4A. To confirm inactivation of vaccinia virus, HLA-A2
+ LCL (30,000 cells/
well) were co-incubated for 24 hrs with vvpp65-infected HLA-A2
2 LCL
(60,000 cells/well) prior to (left well) or after (right well) heat-
inactivation (30 minutes at 56C) and UV-treatment (200mJ
2). Direct
presentation was then detected by IFN-c ELISPOT after an overnight
incubation with CD8
+ T cell clones D2 1-D2 (10,000/well), specific for
the HLA-A2-restricted antigen HCMV pp65.
4B. Representative ELISPOT wells of the cross presentation assay are
shown. DC (30,000/well) from five individual adult (top row) or neonatal
donors (bottom row) were incubated overnight with cell-associated
antigen, namely, vvpp65-infected LCL (60,000/well) that were heat
(30 minutes at 56C) and UV-treated (200 mJ
2). CD8
+ T cell clones D2 1-
D2, specific for the pp65 antigen, were added (10,000 cells/well) and
IFN-c was detected the following day by ELISPOT. Only HLA-A2
+ DC
cross presented the pp65 antigen (right 4 columns) and HLA-A2
2 DC
(left column) never cross presented the antigen. HLA-A2
+ DC incubated
with uninfected HLA-A2
2 LCL never elicited a response by CD8
+ T cell
clone D2-1-D2 (not shown). In addition, vvpp65-infected HLA-A2
2 LCL
alone in the absence of HLA-A2+ DC never elicited a response by CD8
+
T cell clone D2-1-D2 (not shown).
4C. Combined data from 3 separate cross presentation experiments
using adult (n=18) and neonatal (n=14) HLA-A2
+ DC. No significant
differences were observed (p=0.8587).
doi:10.1371/journal.pone.0000957.g004
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antigen processing and presentation. We have directly compared
neonatal and adult DC using identical protocols that would allow
us to discern even modest differences in APC function. Due to the
limited numbers of DC that can be directly isolated from the blood
or tissues of neonates, we were unable to address the function of
neonatal DC directly ex vivo. Nonetheless, in keeping with our
results, studies in mice that have evaluated purified dendritic cells
have demonstrated few intrinsic differences between adult and
neonatal immune cells [20,21]. One difference however is that DC
from neonates express decreased levels of IL-12p35 after LPS
stimulation [12,22]. Nevertheless, the biological effect of this
deficiency is unclear. In in vitro studies, IL-12p70 production could
be restored to adult levels with the addition of IFN-c [23].
Furthermore, in vivo, neonates immunized in the presence of strong
adjuvants can generate adult-like Th1 responses [4,24,25]. Thus,
the impaired capacity of neonates to mount optimal immune
responses may not lie with any specific cell type but may represent
a difference in the environment of the neonate [3]. For example,
Sun et al. showed that Th1 priming in neonatal mice could be
altered by B cells that produced more IL-10 than B cells from
adults [26]. Another example that illustrates an environmental
differences in neonates is the finding that adenosine in neonatal
blood can alter the production of TNF-a and IL-6 from neonatal
monocytes in response to TLR stimulation [27]. Finally, in adults,
but not neonates, cross-reactive T cells could provide some
protection to distinct pathogens [28]. Thus, while the control of
pathogens in neonates is deficient, we conclude that a defect in
antigen processing and presentation function in neonatal dendritic




Human subjects protocols and consent forms were approved by
the Oregon Health & Science University Institutional Review
Board. PBMC were obtained from normal adult donors by
apheresis under written informed consent. Umbilical cord blood
was obtained from healthy full-term neonates. Due to the fact that
cord blood is considered medical waste, and that no identifying
information was collected form the neonates, we obtained cord
blood under an IRB-exempt protocol. Cord blood was collected in
BD Vacutainer CPT and CBMC isolated per manufacturer’s
instructions. Both fresh and cryopreserved cells were used with
equivalent results (data not shown).
Cells, cell lines, and T cell clones
Monocyte-derived DC were prepared according to the method by
Romani et al [29]. Briefly, PBMC or CBMC were resuspended in
2% Human Serum (HS) medium and allowed to adhere to a tissue
culture flask at 37u C for 1 hour. Nonadherent cells were removed
using three PBS washes with gentle rocking. Adherent cells were
incubated with 10% HS medium containing 10 ng/ml of IL-4
(Immunex) and 30 ng/ml of GM-CSF (Immunex). After 5 days,
cells were harvested with cell-dissociation medium (Sigma-Aldrich)
and used as APC in assays. EBV-transformed B cell lines
(lymphoblastoid cell lines, LCL) were generated in our laboratory
using supernatants from the cell line 9B5–8 (American Type
Culture Collection).
The CD8
+ T cell clone D2-1-D2 recognizes the HCMV antigen
pp65(495–503) NLVPMVATV in the context of HLA-A2 and was
generated by limiting dilution analysis as previously described [30]
except that T cells were stimulated using DC infected with the
recombinant vaccinia virus expressing HCMV antigen pp65 (data
not published). CD8
+ T cell clone D160 1-23 recognizes an
antigen derived from the cell wall of Mtb in the context of HLA-E
and has been previously described [10]. CD8
+ T cell clones were
expanded using a rapid expansion protocol with anti-CD3 mAb
stimulation [31].
HLA-A*0201 typing
The assessment of HLA-A2 expression was performed by flow
cytometry on PBMC or CBMC using the FITC-conjugated anti-
HLA-A2 antibody (clone BB7.2) in comparison to a FITC-
conjugated msIgG2 isotype control (clone G155-178) (BD
Pharmingen).
Viruses and Antigens
Recombinant vaccinia virus coding for HCMV pp65 under
control of the vaccinia p7.5 promoter was used for DC infection.
HCMV pp65 peptide nonamer (495-503) NLVPMVATV was used
(Genemed Synthesis, Inc.) for peptide loading of DC. The HLA-E
restricted pronase cell wall antigen was derived as previously
described [10].
Infection of cells with recombinant virus
DC or LCL were pelleted, resuspended in medium (50 ml) and
incubated with vvpp65 at a multiplicity of infection (moi) of 1.5 for
1 hour. Cells were then washed three times, resuspended in 10%
HS RPMI and incubated overnight.
Assays
ELISPOT. The detection of IFN-c production by CD8
+ T cells
was performed by IFN-c ELISPOT as previously described [9]
with the exception that plates were read using the AID High
Resolution Elispot Reader System with a Digital Firewire Camera,
1280x960 Color CCD Chip, QuadPack 2-axis precision stage,
impact-protected, and Pentium PC computer with AID Elispot
Software.
Cross presentation assay. The cross presentation assay described
by Fonteneau et al. was used with several modifications [18]. As
a source of cell-associated antigen we used HLA-A2-negative LCL
that were either uninfected or infected with vvpp65 overnight. To
prevent any direct vaccinia virus infection of the DC in the course
of the experiment, we heated the LCL for 30 minutes at 56uCt o
inactivate the vaccinia virus following overnight infection [32]. We
chose 30 minutes based on time course studies that showed that
30 minutes allowed for inactivation of the virus while maintaining
preservation of the pp65 antigen (data not shown). To induce
apoptosis, LCL were UV treated with 200 mJ
2 and then incubated
for 3 hours in medium at 37uC. LCL were then washed three
times and added to HLA-A2
+ DC (or HLA-A2
2 DC as a control)
in IFN-c-coated ELISPOT plates at a ratio of 2:1 (LCL: DC) and
incubated overnight. D2-1-D2 CD8
+ T cell clones (10,000 cells/
well), specific for NLVPMVATV in the context of HLA-A2, were
added to ELISPOT wells with the DC and incubated overnight.
Detection of IFN-c by T cells was performed the following day.
Statistical Analyses Prism software was used for all statistical
analyses. To determine whether or not there were differences
between neonatal and adult DC in experiments where peptide or
DC number were titrated under limiting conditions, the average
number of spots per well for each duplicate was plotted against the
concentration of peptide or DC number respectively. Linear
regression analysis was used to determine the slope of the line. It
was then determined if the binomial probability for the number of
spots was significantly different between adult and neonatal cells.
Neonatal DC Are Competent APC
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adult and neonatal DC was performed using the Student’s
Unpaired T test.
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